trial · primary record
remibrutinib
Autoimmune and Chronic Inflammatory Diseases
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 16 |
| Primary completion | 2025-10-14 |
| Primary endpoint | Cmax, ss of remibrutinib in blood |
| Registry ID | NCT07032272 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:45.002Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07032272
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.